Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He leads a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology
Awards, Training and Qualifications
- MB BS University of London 1990
- DPhil University of Oxford 1998
- FRCP Royal College of Physicians, London 2006
MB BS, DPhil, FRCP
Head of Department and Professor of Motor Neuron Biology
Division of Clinical Neurology
Kavli Institute for Nanoscience Discovery
The main aim of my research is to identify targets for therapy in motor neuron diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy. In particular, we use laboratory models including motor neurons from induced pluripotent stem cells from patients to understand why motor neuron integrity fails in the presence of certain genetic mutations (eg; TDP-43 or C9orf72 in ALS). We also use these models to identify drug targets. Our work takes place in the context of a larger team of researchers in Oxford interested in translational research in neurodegenerative diseases, and we have many national and international collaborations.
Professor Talbot is not currently accepting new DPhil students.
Sources of Funding
- Motor Neuron Disease Association 2001 - 2021
- Thierry Latran Foundation 2018 - 2020
- SMA Trust 2006 - 2020
- My Name'5 Doddie Foundation 2019 - 2022
A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning.
De Oliveira HM. et al, (2022), Amyotroph Lateral Scler Frontotemporal Degener, 1 - 9
Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Joilin G. et al, (2022), Ann Med, 54, 3069 - 3078
The impact of age on genetic testing decisions in amyotrophic lateral sclerosis.
Mehta PR. et al, (2022), Brain
Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins.
Gao J. et al, (2022), Sci Transl Med, 14
Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months.
Young CA. et al, (2022), Amyotroph Lateral Scler Frontotemporal Degener, 1 - 9